You are here

  • Home
  • Archive
  • Volume 11, Issue 5
  • Response to a 2 week continuous positive airway pressure trial accurately identified patients with obstructive sleep apnoea syndrome

Article Text

Article menu
Download PDFPDF
Diagnosis
Response to a 2 week continuous positive airway pressure trial accurately identified patients with obstructive sleep apnoea syndrome

https://doi.org/10.1136/ebm.11.5.152

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Senn O, Brack T, Russi EW, et al. A continuous positive airway pressure trial as a novel approach to the diagnosis of the obstructive sleep apnea syndrome. Chest 2006;129:67–75.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients with suspected obstructive sleep apnoea syndrome (OSA), does a self reported positive response to a 2 week continuous positive airway pressure (CPAP) trial with >2 hours of documented CPAP use per night accurately identify patients with OSA?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Respirology ★★★★★★☆

    METHODS

    Embedded ImageDesign:

    blinded comparison of response to a 2 week CPAP trial with polysomnography.

    Embedded ImageSetting:

    a sleep disorder centre in Zurich, Switzerland.

    Embedded ImagePatients:

    76 patients (mean age 52 y, 80% men) with suspected OSA (habitual snorer, complaint of daytime sleepiness, and an Epworth sleeping scale score ⩾8). Exclusion criteria included a contraindication for CPAP (unstable congestive heart failure, significant lung disease, or obesity hypoventilation); significant nasal obstruction; a history of any sleep disease and CPAP treatment; or a diagnosis of an internal medical, neurological, or psychiatric disease …

    View Full Text

    Footnotes

    • For correspondence: Dr K E Bloch, University Hospital of Zurich, Zurich, Switzerland. pneubloc{at}usz.unizh.ch

    • Source of funding: Lung Leagues of Zurich and Schaffhausen.